Pernix Therapeutics Holdings, a specialty pharmaceutical company, today announced the completion of a new three-year $50 million revolving credit facility with Wells Fargo. The new facility bears an interest rate of LIBOR plus 1.5% to LIBOR plus 2.0%...
Read Story
August 25, 2015, 07:19 AM
|
Pernix Therapeutics Holdings, Inc. announced that it has closed on the issuance of $65 million aggregate principal amount of 8.00% Convertible Senior Notes due 2019 (the “Notes”) to a group of institutional investors led by Athyrium Capital...
Read Story
February 26, 2014, 07:05 AM
|
Pernix Therapeutics Holdings, a specialty pharmaceutical company, has completed the acquisition of Cypress Pharmaceuticals, Inc., a privately owned generic pharmaceutical company, and Hawthorn Pharmaceuticals, Inc., a privately owned branded...
Read Story
January 03, 2013, 07:37 AM
|